Provided by Tiger Trade Technology Pte. Ltd.

Defiance Daily Target 2X Short LLY ETF

8.57
0.0000
Volume:- -
Turnover:- -
Market Cap:1.54M
PE:- -
High:8.57
Open:8.57
Low:8.57
Close:8.57
52wk High:16.63
52wk Low:7.63
Shares:180.00K
Float Shares:180.00K
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly & Co (LLY) Gets a Buy from RBC Capital

TIPRANKS
·
2 hours ago

Former Eli Lilly Exec Sells Wyoming Estate for Close to $39.5 Million

Dow Jones
·
8 hours ago

Eli Lilly announces FDA approves additional indication for Jaypirca

TIPRANKS
·
9 hours ago

Lilly Says FDA Approves Expanded First-Line Cll/sll Use for Jaypirca

Reuters
·
9 hours ago

Lilly's Jaypirca (Pirtobrutinib), the First-and-Only Approved Non-Covalent Btk Inhibitor, Receives Expanded Indication from U.S. FDA for Certain Patients with Previously Untreated Cll/Sll

THOMSON REUTERS
·
9 hours ago

Correction: Top Midday Decliners

MT Newswires Live
·
Yesterday

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Yesterday

Sector Update: Healthcare

MT Newswires Live
·
Yesterday

Trump Medicare Drug Pricing Model May Apply to Only Four Companies After Exemptions

Reuters
·
Yesterday

Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says

MT Newswires Live
·
Yesterday

Eli Lilly (LLY) Ends Cancer Development Deal with Foghorn Therapeutics

TIPRANKS
·
Oct 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)

TIPRANKS
·
Oct 01

Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials with Ely Lilly

Dow Jones
·
Oct 01

Lilly Says Foundayo Cuts Predicted 10-Year Type 2 Diabetes Risk 57% in Attain-1 Post-Hoc Analysis

Reuters
·
Oct 01

Eli Lilly - Foundayo 17.2 Mg Associated with 57% Reduction in Diabetes Risk, 18% in Cardiovascular Risk Versus Placebo

Reuters
·
Oct 01

Eli Lilly - Foundayo Associated with Reduced Predicted Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease

THOMSON REUTERS
·
Oct 01

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Dow Jones
·
Oct 01

Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial

Dow Jones
·
Oct 01

Eli Lilly’s Foundayo shows cardiovascular safety in type 2 diabetes study

TIPRANKS
·
Oct 01

Lilly's Oral Glp-1, Foundayo (Orforglipron), Demonstrated Cardiovascular Safety Alongside Sustained A1c Reduction and Weight Loss in Its Largest and Longest Type 2 Diabetes Study

THOMSON REUTERS
·
Oct 01